BR112021018205A2 - Pequenos agentes bloqueadores de liberação. - Google Patents

Pequenos agentes bloqueadores de liberação.

Info

Publication number
BR112021018205A2
BR112021018205A2 BR112021018205A BR112021018205A BR112021018205A2 BR 112021018205 A2 BR112021018205 A2 BR 112021018205A2 BR 112021018205 A BR112021018205 A BR 112021018205A BR 112021018205 A BR112021018205 A BR 112021018205A BR 112021018205 A2 BR112021018205 A2 BR 112021018205A2
Authority
BR
Brazil
Prior art keywords
blocking agents
small release
release blocking
agents
immune receptor
Prior art date
Application number
BR112021018205A
Other languages
English (en)
Inventor
Alishekevitz Dror
Ben-Moshe Tehila
Fridman-Dror Anna
Hakim Motti
Mandel Ilana
Meilin Edna
Sapir Yair
Shulman Avidor
Original Assignee
Biond Biologics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biond Biologics Ltd filed Critical Biond Biologics Ltd
Publication of BR112021018205A2 publication Critical patent/BR112021018205A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

pequenos agentes bloqueadores de liberação. são fornecidos agentes com menos de 100 quilodaltons que se ligam a um receptor imunológico membranal em uma superfície de uma célula e inibem a clivagem proteolítica do receptor imunológico. métodos de tratamento de câncer e melhoria da imunoterapia compreendendo a administração dos agentes também são fornecidos.
BR112021018205A 2019-03-14 2020-03-12 Pequenos agentes bloqueadores de liberação. BR112021018205A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962818351P 2019-03-14 2019-03-14
US201962942240P 2019-12-02 2019-12-02
US201962954802P 2019-12-30 2019-12-30
PCT/IL2020/050297 WO2020183473A1 (en) 2019-03-14 2020-03-12 Small shedding blocking agents

Publications (1)

Publication Number Publication Date
BR112021018205A2 true BR112021018205A2 (pt) 2021-12-28

Family

ID=70334001

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112021018205A BR112021018205A2 (pt) 2019-03-14 2020-03-12 Pequenos agentes bloqueadores de liberação.

Country Status (11)

Country Link
US (1) US20220169732A1 (pt)
EP (1) EP3938397A1 (pt)
JP (1) JP2022525407A (pt)
KR (1) KR20210141544A (pt)
CN (1) CN113710704A (pt)
AU (1) AU2020234111A1 (pt)
BR (1) BR112021018205A2 (pt)
CA (1) CA3130351A1 (pt)
IL (1) IL286377A (pt)
SG (1) SG11202110032TA (pt)
WO (1) WO2020183473A1 (pt)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021235569A1 (en) * 2020-03-12 2022-10-06 Biond Biologics Ltd. Shedding blocking agents with increased stability
AU2022341016A1 (en) * 2021-09-06 2024-04-18 Biond Biologics Ltd. Cd28 shedding blocking agents

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
CN100509849C (zh) * 2005-04-07 2009-07-08 苏州大学 可溶性人cd28分子检测试剂盒及其应用
WO2010009391A1 (en) * 2008-07-18 2010-01-21 Bristol-Myers Squibb Company Compositions monovalent for cd28 binding and methods of use
CN112074539A (zh) * 2018-03-15 2020-12-11 比昂生物制剂公司 降低可溶性免疫受体cd28的方法和组合物

Also Published As

Publication number Publication date
US20220169732A1 (en) 2022-06-02
JP2022525407A (ja) 2022-05-13
KR20210141544A (ko) 2021-11-23
WO2020183473A1 (en) 2020-09-17
CN113710704A (zh) 2021-11-26
AU2020234111A1 (en) 2021-10-14
EP3938397A1 (en) 2022-01-19
IL286377A (en) 2021-10-31
SG11202110032TA (en) 2021-10-28
CA3130351A1 (en) 2020-09-17

Similar Documents

Publication Publication Date Title
BR112020002012A8 (pt) Anticorpos anti-cd39, composições que compreendem anticorpos anti-cd39 e métodos de utilização de anticorpos anti-cd39
AR126205A2 (es) Métodos de uso de linfocitos infiltrantes de tumor en melanoma doble refractario
BR112016025009A2 (pt) anticorpos humanos para a síndrome respiratória do oriente médio - proteína de superfície
EP4257600A3 (en) Antibodies that target hiv gp120 and methods of use
BR112017019140A2 (pt) métodos de tratamento de câncer usando células t ativadas
BR112012018951B8 (pt) anticorpo monoclonal, composição farmacêutica, combinação farmacêutica, uso de um anticorpo, uso de uma composição farmacêutica e uso de uma combinação farmacêutica
EA202190377A9 (ru) Композиции ингибиторов cxcr4 и способы получения и применения
BR112018016054A2 (pt) composições farmacêuticas e/ou métodos para tratar câncer e/ou para romper vasculatura de tumor associada ao câncer em indivíduo
SG10201900072VA (en) A pharmaceutical combination and method for regulation of tumor microenvironment and immunotherapy
BR112021018205A2 (pt) Pequenos agentes bloqueadores de liberação.
BR112021024978A2 (pt) Composições engajadoras específicas para macrófagos e métodos de uso das mesmas
BR112021021645A2 (pt) Anticorpos anti-hvem e uso dos mesmos.
BR112017004202A2 (pt) composições para intensificar respostas imunes e seus usos
EA202191257A1 (ru) Противораковая терапия на основе иммуноцитов, связывающих liv1
BR112021022514A2 (pt) Conjugados de anticorpo e fármaco
BR112022006440A2 (pt) Receptor de antígeno quimérico intensificado para manipulação de célula efetora imune e uso do mesmo
BR112022007158A2 (pt) Agentes imunomodulatórios de il-2 em combinação com inibidores do ponto de verificação imunológico
MX2022006932A (es) Combinaciones de inhibidores de diacilglicerol cinasas (dgk) y antagonistas de puntos de control.
MX2023001287A (es) Bancos universales de células t específicas de antígeno y métodos de fabricación y uso terapéutico de los mismos.
BR112021014944A2 (pt) Toxinas apxia, apxiia e apxiiia inativas
WO2020106358A8 (en) Novel anti-zika virus antibodies and uses thereof
MX2019010707A (es) Metodos para tratar y/o prevenir queratosis actinica.
BR112018003291A2 (pt) modulando a expressão da apolipoproteina (a)
BR112021025116A2 (pt) Células linfocíticas ativadas e métodos de uso das mesmas para tratar câncer e condições infecciosas
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]